Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4005 - Elderly patients in the Japanese Breast Cancer Registry

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Masataka Sawaki

Citation

Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240

Authors

M. Sawaki1, A. Yamada2, H. Kumamaru3, H. Miyata3, C. Shimizu4, M. Miyashita5, N. Honma6, N. Taira7, S. Saji8

Author affiliations

  • 1 Breast Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 2 Gastroenterological Surgery, Yokohama City University School of Medicine, 2360004 - Yokohama/JP
  • 3 Healthcare Quality Assessment, Graduate School of Medicine, Tokyo University, 1130003 - Tokyo/JP
  • 4 Breast Medical Oncology, National Center for Global Health and Medicine, 162-8655 - Tokyo/JP
  • 5 Nursing Science, Graduate School of Biomedical and Health Sciences, Hiroshima University, 734-8551 - Hiroshima/JP
  • 6 Pathology, Toho University School of Medicine, 143-8540 - Tokyo/JP
  • 7 Breast And Endocrine Surgery, Okayama University Hospital, 700-8558 - Okayama/JP
  • 8 Medical Oncology, Fukushima Medical University, 960-1247 - Fukushima/JP
More

Resources

Abstract 4005

Background

Aim: To clarify the clinicopathological characters and treatments and prognosis in elderly breast cancer patients using the Japanese Breast Cancer Registry (JBCR) system.

Methods

We reviewed data from JBCR, which is the nation-wide registry of newly diagnosed and operated primary breast cancer patients in Japan. To clarify its characteristics, we compared elderly patients aged 75 and over (elderly) with aged from 65 to 74 (young-old; y-o) and that from 55 to 64 (post-menopausal; p-m), respectively.

Results

In total 132,240 cases diagnosed between 2004 and 2011 were reviewed (elderly; n = 27,385, y-o; n = 43,839, p-m; n = 61,016). In histology, the proportion of mucinous carcinoma and apocrine carcinoma were higher in elderly (6.1%, 1.8%, y-o; 3.5%, 1.7%, p-m; 1.8%, 1.3%, respectively). Patients with clinical stage II and III were more frequent in elderly (45.1%, y-o; 39.0%, p-m; 39.8%). ER -positive rate was higher (76.8%, y-o; 76.3%, p-m; 72.7%) and HER2-positive rate was lower in elderly (10.5%, y-o; 12.8%, p-m; 18.6%, p < 0.001). As for surgery, the rate of breast conserving surgery (BCS) was lower in elderly (46.4%, y-o; 55.0%, p-m; 59.6%), and the rate of no surgery for axilla was higher in elderly (18.4%, y-o; 5.9%, p-m; 4.8%, p < 0.001). Irradiation after BCS was performed only in 41.3% of elderly patients, whereas y-o and p-m were 75.9%, 83.0%, respectively. Adjuvant chemotherapy was performed only in 10.8% of elderly patients, y-o and p-m were 31.8%, 46.2%, respectively. Half of elderly patients (49.8%) who underwent chemotherapy were given CMF or oral 5FU. As for hormone therapy, Tamoxifen was used more frequently in elderly (18.1%, y-o; 10.6%, p-m; 9.7%). The 5 years-survival analysis is shown in Table.Table:

238P

Age≧7565-7455-64
Distant disease-free survival (%)93.194.393.1
Overall survival (%)84.393.794.4
Breast cancer-specific survival (BCSS) (%)94.296.795.9
Other disease death (%)48.035.820.6

Conclusions

Elderly patients suffered from more advanced disease at the time of diagnosis. Irradiation after BCS and primary systemic chemotherapy was more frequently omitted in the elderly patients. Overall, BCSS was similar among ages, but the rate of other causes of death was higher in elderly patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Japanese Breast Cancer Society.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings